Our experts will be onsite at JP Morgan (San Francisco, January 13-16, 2025). Join them to explore commercialization models and options for your assets. Learn how EVERSANA makes it easy and smarter to commercialize or build value for your asset. EVERSANA offers alternatives to selling, out-licensing or launching internally. Join us for a conversation.
Schedule a meeting for:
- Emerging Biotech exploring their first launch
- Pharma Executives with established product portfolio
- Investors seeking predictability
The life sciences sector has been long overdue for transformation. Fueled by increasing pressures on both established and emerging pharmaceutical companies, combined with investment market volatility, regional and regulatory complexities, and the need to improve both brand value and patient impact, we reinvented commercialization.
EVERSANA provides the industry’s only option for fully integrated commercial services to solve any drug pricing, promotion, access, reimbursement, adherence, or product delivery challenge.
Transformed by data and digital innovation, EVERSANA activates our future-ready infrastructure and proven industry expertise to manage the complete launch and commercialization of your product portfolio or address specific program or patient needs.
Explore our commercial models:
- EVERSANA COMPLETE Commercialization– full access to ready-to-deploy, high-performance commercialization and distribution engine; mitigate the risk of having to build commercial infrastructure
- EVERSANA REIGNITE – built for large pharma established brand portfolios – Maximize product value before its loss of exclusivity, and optimize revenue at the late stages of the product life cycle
Meet our experts at Biotech Showcase:
Informa’s Biotech Showcase™ during JPM week
San Francisco, CA – Tuesday, January 14, 2025 – 3:30-3:50pm Pacific
Fireside Chat: Unlocking Your Product’s Full Value: The Benefits of Early Commercial Development
Early commercial development is crucial for life sciences companies aiming to secure funding, partnerships and maximizing the full potential of their products. By shaping a complete clinical and commercial value proposition, understanding customer needs, and creating market access tailwinds, companies can lay a strong foundation to create value for all stakeholders. This session will explore how early commercial development supports capital raises, enhances partnership prospects, and ensures a successful path towards improving patient outcomes.
Speakers:
- Sharon Cunningham, Chief Executive Officer, Shorla Oncology
- Faruk Abdullah, President, Professional Services and Chief Business Officer, EVERSANA